Aprea Therapeutics Inc expected to post a loss of $3.08 a share - Earnings Preview

Aprea Therapeutics

17/03/2023 11:27

* Aprea Therapeutics Inc  APRE.OQ   APRE.O  is expected
to show no
change in quarterly revenue when it reports  results on March 20
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Aprea Therapeutics
Inc is
for a loss of $3.08 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Aprea
Therapeutics Inc is $60​, above​ its last closing price
of $5.15. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -9.20       -5.50      -2.40     Beat    56.4
 Jun. 30 2022  -7.00       -7.50      -19.60    Missed  -161.3
 Mar. 31 2022  -7.60       -7.60      -7.20     Beat    5.3​
 Dec. 31 2021  -8.80       -8.80      -7.20     Beat    18.2
 ​​Sep.        -9.04       -9.05      -9.00     Beat    0.6
 30 2021                                                
 Jun. 30 2021  -9.11       -9.35      -9.60     Missed  -2.7​
 Mar. 31 2021  -9.70       -9.85      -9.20     Beat    6.6
 Dec. 31 2020  -13.49      -12.85     -14.60    Missed  -13.6
 This summary was machine generated March 17 at 11:27 GMT.  All
figures in US dollars  unless otherwise stated